MicroRNA biomarkers of type 2 diabetes: evidence synthesis from meta-analyses and pathway modelling
Authors' conclusion
Sixteen microRNAs met the criteria for biomarker selection. In terms of both significance and relevance, the order of priority for verification of these microRNAs is as follows: miR-29a-3p, miR-221-3p, miR-126-3p, miR-26a-5p, miR-503-5p, miR-100-5p, miR-101-3p, mIR-103a-3p, miR-122-5p, miR-199a-3p, miR-30b-5p, miR-130a-3p, miR-143-3p, miR-145-5p, miR-19a-3p and miR-311-3p.
Study context
- Population
- Controlled microRNA expression profiling studies of T2D (PubMed, ScienceDirect, Web of Science) and microRNA-regulated T2D pathway delineation studies
- Participants
- >15,000 participants156 profiling studies
- Comparison
- T2D vs controls
- Outcome
- Consistently and significantly dysregulated microRNAs in T2D
Methodological detailssubgroup and sensitivity analyses, signalling pathway impact analysis
- Subgroup and sensitivity analyses
- Signalling pathway impact analysis
Pooled result
As reported in the abstract
Differentially expressed microRNAs identified
404
Both consistently and significantly dysregulated in human T2D
60
Robust in sensitivity analyses
58
Dysregulated microRNAs significantly enriched in augmented Kyoto Encyclopedia of Genes and Genomes (KEGG) T2D pathway
16
Further pooled results
Tissue specificity (subgroup analyses)
- No microRNAs consistently and significantly dysregulated in multiple tissues
Pathway delineation
- Pathway delineation studies
- 1966
- microRNA-target interactions
- 3290
- microRNA-regulated pathways
- 225
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →